Coya Therapeutics (COYA)
4.64
+0.23 (5.22%)
Upcoming Events
Latest Headlines
Coya Therapeutics begins extension phase of ALS drug trial
June 8, 2026 8:00 AM - StreetInsider
Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase
June 8, 2026 8:00 AM - BizWire
Roth/MKM Starts Coya Therapeutics (COYA) at Buy
June 5, 2026 2:13 AM - StreetInsider
Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit
May 27, 2026 8:00 AM - BizWire
Form ARS Coya Therapeutics, Inc. For: Dec 31
May 13, 2026 8:34 AM - SEC Filing
Form DEFA14A Coya Therapeutics, Inc.
May 13, 2026 8:32 AM - SEC Filing
Form DEF 14A Coya Therapeutics, Inc. For: Jun 25
May 13, 2026 8:30 AM - SEC Filing
Coya Therapeutics, Inc. (COYA) Tops Q1 EPS by 37c
May 12, 2026 8:59 AM - StreetInsider
Form 8-K Coya Therapeutics, Inc. For: May 12
May 12, 2026 8:48 AM - SEC Filing
Form 424B5 Coya Therapeutics, Inc.
May 12, 2026 8:44 AM - SEC Filing
Form 10-Q Coya Therapeutics, Inc. For: Mar 31
May 12, 2026 7:42 AM - SEC Filing
Form 8-K Coya Therapeutics, Inc. For: May 12
May 12, 2026 7:39 AM - SEC Filing
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
May 12, 2026 7:35 AM - BizWire
Coya Therapeutics receives FDA fast track designation for ALS treatment
May 12, 2026 7:30 AM - StreetInsider
Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
May 12, 2026 7:30 AM - BizWire
Form 4 Coya Therapeutics, Inc. For: Apr 09 Filed by: Pavao Mark H
April 9, 2026 6:50 PM - SEC Filing
Form 3 Coya Therapeutics, Inc. For: Apr 01 Filed by: Pavao Mark H
April 9, 2026 6:43 PM - SEC Filing
Coya Therapeutics publishes study linking ALS biomarkers to survival
April 9, 2026 8:01 AM - StreetInsider
Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS
April 9, 2026 8:00 AM - BizWire
Form 8-K Coya Therapeutics, Inc. For: Mar 29
April 2, 2026 8:49 AM - SEC Filing
COYA Therapeutics founder steps down, appoints Pavao to board
April 2, 2026 8:01 AM - StreetInsider
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director
April 2, 2026 8:00 AM - BizWire
ReAlta names Howard Berman CEO and Kia Motesharei president and COO
March 24, 2026 8:01 AM - StreetInsider
ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COO
March 24, 2026 8:00 AM - BizWire
Form EFFECT Coya Therapeutics, Inc.
March 23, 2026 6:07 AM - SEC Filing
Form 424B3 Coya Therapeutics, Inc.
March 20, 2026 4:32 PM - SEC Filing
Coya Therapeutics study shows immune dysfunction in dementia patients
March 18, 2026 8:00 AM - StreetInsider
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring
March 18, 2026 8:00 AM - BizWire
Coya Therapeutics (COYA) files for 2.5M share offering by selling stockholders
March 16, 2026 9:22 AM - StreetInsider
Form S-3 Coya Therapeutics, Inc.
March 16, 2026 9:21 AM - SEC Filing
Form 10-K Coya Therapeutics, Inc. For: Dec 31
March 16, 2026 8:12 AM - SEC Filing
Form 8-K Coya Therapeutics, Inc. For: Mar 16
March 16, 2026 8:08 AM - SEC Filing
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results
March 16, 2026 8:00 AM - BizWire
Full Article List
